Wedbush Securities has published a research report on HeartWare International HTWR and reiterates its rating on the company at Outperform.
In the report, Wedbush writes, “Our fair value of $105 per share is calculated using a sum-of-parts analysis applying 1-5 multiple and a 20-25% annual discount to our HVAD sales in 2012 (EU) or two-years post approval (US). Given the groundbreaking nature of HeartWare's HVAD, the enthusiastic response from surgeons, and the lack of near-term financing risk, we reiterate our OUTPERFORM rating.”
HTWR closed Friday at $64.41.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in